Octapharma Plasma
Octapharma Plasma operates 180+ US plasma donation centers as the collection arm of Octapharma AG, paying individual donors to supply plasma that is fractionated into therapies for 300+ rare and chronic conditions.
- Company typePrivate
- Founded2008
- HeadquartersCharlotte, United States
- Headcount5,001–10,000
- GTM typeB2C
- OfferingServices
What Octapharma Plasma does
Octapharma Plasma, Inc. (OPI) is the US plasma-collection subsidiary of Swiss pharmaceutical group Octapharma AG. Headquartered in Charlotte, North Carolina, OPI operates more than 180 physical plasma donation centers across the United States where adult donors contribute plasma via automated plasmapheresis and receive financial compensation. The company reports a workforce of approximately 4,906 employees (firmographic band 5,001-10,000), with leadership disclosure indicating 69% employees of color and 67% women. OPI serves two distinct constituencies: (i) individual plasma donors who supply biological material up to twice weekly, motivated by compensation, flexible scheduling, and altruism, and (ii) downstream patients with rare and chronic conditions such as hemophilia, primary immunodeficiency, autoimmune disorders, and trauma, whose plasma-derived therapies require 130-1,200 donations per patient per year and address over 300 conditions.
The company's product surface spans the physical donation experience and a recently built digital ecosystem. The OctaApp mobile application (iOS and Android) integrates appointment scheduling, OctaPass (online pre-screening questionnaire completed within two hours of donation), OctaRewards (a non-expiring loyalty point program), and access to the web-based Donor Portal. New donors can earn up to $750 in compensation during their first 35 days. Plasma collection is performed using automated plasmapheresis equipment that separates plasma from whole blood and returns red blood cells to the donor; the process takes 45-90 minutes and is repeatable twice weekly with 48-hour intervals.
OPI operates as a captive supply chain for Octapharma AG: plasma is collected from donors and sold internally to the parent for fractionation into immunoglobulins, albumin, and clotting factors. The company is privately held, incorporated in North Carolina, and not publicly traded. Beyond its core collection operation, OPI engages in patient-advocacy partnerships such as with the Ree Wynn Foundation (October 2024) for TTP awareness and runs multi-channel donor acquisition and retention through the OctaApp, website, paid and organic social media, SEO, donor referral programs, and International Plasma Awareness Week events. No AI/ML capabilities, patents, or third-party AI integrations are disclosed.
Octapharma Plasma firmographics
Firmographics- Name
- Octapharma Plasma
- Legal name
- Octapharma Plasma, Inc.
- Website
- https://octapharmaplasma.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Octapharma Plasma operates 180+ US plasma donation centers as the collection arm of Octapharma AG, paying individual donors to supply plasma that is fractionated into therapies for 300+ rare and chronic conditions.
- Ownership category
- akta.pro rank
Octapharma Plasma industry classification
Industry- Product category
- Plasma Collection Services
- NAICS
- Blood and Organ Banks (621991)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Plasma Collection & Donor Services (Plasmapheresis Centers) (HLAIAHAH)
- akta.pro secondary industries
- Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors) (HLAAAAAI), Plasma-Derived & Blood Products Distributors (HLAIAJAJ), Blood, Organ & Tissue Donation Organizations (BPAGACAJ)
Keywords
Where Octapharma Plasma is headquartered
LocationHeadquarters
- HQ city
- Charlotte
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Octapharma Plasma business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Infrastructure, Technology or R&D
Revenue model
- Plasma Collection and Sale: Octapharma Plasma collects plasma from donors and sells it to Octapharma AG (parent company) for manufacturing into plasma-derived therapies. Revenue is generated through compensation paid to donors (treated as cost of goods), with income derived from processed plasma products including immunoglobulins, albumin, and clotting factors.
- Donor Compensation: Donors receive financial compensation for plasma donations, with new donors able to earn up to $750 during their first 35 days. Compensation varies by location and donation frequency (up to twice weekly).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Per donation | New Donor Compensation - Up to $750 in first 35 days |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels7 records
Octapharma Plasma product offering
Product offeringCore offering
Octapharma Plasma operates a network of 180+ plasma donation centers across the United States where individual donors contribute plasma through automated plasmapheresis in exchange for financial compensation. The collected plasma is supplied to parent company Octapharma AG for manufacturing into plasma-derived therapies that treat more than 300 conditions, including hemophilia, primary immunodeficiency, and autoimmune disorders. New donors can earn up to $750 in compensation during their first 35 days, with donations possible up to twice weekly.
Product overview
Octapharma Plasma operates a plasma donation network with over 180 centers across the United States. The company offers a unified donor experience centered around the OctaApp mobile application, which serves as the primary digital interface integrating OctaPass (online pre-screening), OctaRewards (loyalty program), and donor account access. The Donor Portal provides complementary web-based functionality for viewing test results and donation history. The core offering is plasma collection services, where donated plasma is processed into therapies treating over 300 conditions including hemophilia, primary immunodeficiency, and chronic inflammatory demyelinating polyneuropathy.
Differentiator
Problem solved
Functional benefit
Products and services
- Plasma Donation Services Plasma collection service where donors contribute plasma used to create life-saving therapies for patients with rare and chronic conditions including hemophilia, immune deficiencies, and autoimmune disorders. Donors can earn up to $750 in the first 35 days.
- OctaApp Mobile application enabling donors to schedule appointments, access OctaPass for online screening, view payment information, and manage OctaRewards loyalty points. Available on Google Play and Apple App Store.
- Donor Portal
Quantifiable outcome
- 800,000+ patients helped through plasma-derived therapies
- +3 more outcomes
Companies that use Octapharma Plasma
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles3 records
Octapharma Plasma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Octapharma Plasma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Ree Wynn Foundation (RWF)minorPartnership to raise awareness for Thrombotic Thrombocytopenic Purpura (TTP). During International Plasma Awareness Week October 2024, Octapharma Plasma coordinated its first plasma drive at two donation centers in New Jersey in collaboration with RWF. The foundation educates and promotes TTP awareness to reduce mortality rates and enhance quality of life for those living with this rare blood disorder.
Scale indicators6 records
Recent moves5 records
Expansion highlights4 records
Octapharma Plasma competitors and assessment
Company assessmentDirect peers
- BPL Plasma: US paid-plasma collection network operated by Bio Products Laboratory, a global plasma fractionator. Direct competitor in donor acquisition and supplies its parent's fractionation needs.
- BioLife Plasma Services: Plasma collection subsidiary of Takeda operating a large US center network with paid donor compensation. Direct competitor for donors and supplies plasma to its parent's fractionation operations, mirroring Octapharma Plasma's structure.
- KEDPlasma: US plasma donation network historically tied to Kedrion, operating paid donor centers across multiple states. Direct competitor for donors with the same per-donation compensation structure.
- ADMA Biocenters: US plasma collection business owned by ADMA Biologics that supplies source plasma for hyperimmune and immunoglobulin therapies. Direct comparator in the paid-donor plasma collection niche.
- CSL Plasma: Largest US paid-plasma collection network and a direct competitor. Operates hundreds of donation centers with the same donor-compensation model and supplies plasma to CSL Behring for fractionation — the closest analogue to Octapharma Plasma's role within Octapharma AG.
Regional players
- Canadian Plasma Resources: Canadian paid-plasma collection operator with a comparable paid-donor model. Comparable on business model and process but operates in a different regulatory and geographic market than Octapharma Plasma.
- GCAM Plasma: Paid-plasma collection network focused primarily on Texas and surrounding Sun Belt states. Comparable operating model and donor experience, but more regional in scope than Octapharma Plasma's national footprint.
Broad incumbents
- Grifols: Global plasma-derived therapies manufacturer that also operates its own US plasma collection network (e.g., Biomat USA, Talecris Plasma Resources). Comparable because it is both a fractionator and a competitor collector, though broader in scope than Octapharma Plasma.
- Kedrion: Plasma-derived therapeutics manufacturer with collection operations in the US and Europe. Comparable as an integrated collector-frationator, though its collection footprint is smaller and less US-centric than Octapharma Plasma's.
Others
- Vitalant: Large US nonprofit blood and plasma collector focused on volunteer (unpaid) donations. Not a direct competitor for paid plasma but operates in the adjacent whole-blood/plasma collection ecosystem with overlap in regulatory and operational complexity.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Octapharma Plasma social profiles
Digital presenceOctapharma Plasma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Octapharma Plasma leadership team
Management profileNumber of profiles
Profiles7 records
Octapharma Plasma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Octapharma Plasma M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Octapharma Plasma
What does Octapharma Plasma do?
Octapharma Plasma operates a network of 180+ plasma donation centers across the United States where individual donors contribute plasma through automated plasmapheresis in exchange for financial compensation. The collected plasma is supplied to parent company Octapharma AG for manufacturing into plasma-derived therapies that treat more than 300 conditions, including hemophilia, primary immunodeficiency, and autoimmune disorders. New donors can earn up to $750 in compensation during their first 35 days, with donations possible up to twice weekly.
Is Octapharma Plasma a public or private company?
Octapharma Plasma is a private company. It is classified as corporate owned and is currently operating.
When was Octapharma Plasma founded?
Octapharma Plasma was founded in 2008. It employs 5,001 to 10,000 people.
Where is Octapharma Plasma based?
Octapharma Plasma is headquartered in Charlotte, United States, in the North America region.
How does Octapharma Plasma make money?
Two revenue lines are on record. Plasma Collection and Sale is the primary driver. The others are donor Compensation.
Who are Octapharma Plasma's main competitors?
Direct peers on record are BPL Plasma, BioLife Plasma Services, KEDPlasma, ADMA Biocenters and CSL Plasma. Regional players are Canadian Plasma Resources and GCAM Plasma. Broad incumbents are Grifols and Kedrion. Vitalant is listed as an others.
Does Octapharma Plasma have an API?
No public API is recorded for Octapharma Plasma.
What industry is Octapharma Plasma in?
Octapharma Plasma's product category is Plasma Collection Services. Its primary akta.pro industry code is HLAIAHAH, Plasma Collection & Donor Services (Plasmapheresis Centers), with a secondary code of HLAAAAAI, Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors). Its NAICS code is 621991 and its SIC code is 5122.